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Abstract
Background: Antibiotic resistance is an increasing problem in isolates of Staphylococcus aureus (S. aureus) worldwide. 
In 2001 The National Health Service in the UK introduced a mandatory bacteraemia surveillance scheme for the 
reporting of S. aureus and methicillin-resistant S. aureus (MRSA). This surveillance initiative reports on the percentage of 
isolates that are methicillin resistant. However, resistance to other antibiotics is not currently reported and therefore the 
scale of emerging resistance is currently unclear in the UK. In this study, multiple antibiotic resistance (MAR) profiles 
against fourteen antimicrobial drugs were investigated for 705 isolates of S. aureus collected from two European study 
sites in the UK (London) and Malta.
Results: All isolates were susceptible to linezolid, teicoplanin and vancomycin. Multiple antibiotic resistance profiles 
from both countries were determined, a total of forty-two and forty-five profiles were seen in the UK cohort (MRSA and 
MSSA respectively) and comparatively, sixty-two and fifty-two profiles were shown in the Maltese group. The largest 
MAR profile contained six antibiotics (penicillin G, methicillin, erythromycin, ciprofloxacin, clindamycin and 
clarithromycin) and was observed in the MRSA isolates in both the UK and Maltese cohorts.
Conclusion: The data presented here suggests that the monitoring of changing resistance profiles locally in 
maintaining treatment efficacy to resistant pathogens.
Background
Staphylococcus aureus and particularly methicillin-resis-
tant S. aureus (MRSA) have become a major problem in
hospital acquired infections (HAIs) worldwide. The
World Health Organisation (WHO) recognizes that anti-
biotic resistance is one of the major threats facing the
world in the future [1].
Between 1991 and 2000 the Department of Health
(DoH) in the UK reported that bacteraemia cases caused
by MRSA in the UK rose from 2% to 40% [2]. In April
2001 the National Health Service in the UK introduced a
mandatory bacteraemia surveillance scheme for S.
aureus. Current levels of S. aureus bacteraemia are
reported to be between 9,000-10,000 cases per annum in
the UK of which 38-40% of cases are attributed to
MRSA[3,4]. However, these reports only state the inci-
dence of methicillin resistance and do not include the
occurrence of resistance to other clinically important
antibiotics. As both methicillin-sensitive S. aureus
(MSSA) and MRSA are resistant to multiple antibiotics,
full multiple antibiotic resistance (MAR) profiles are
required to aid successful therapy and maintain an under-
standing of the ever changing dynamics of antimicrobial
resistance.
The aim of this study was to carry out a comparative
assessment of MAR profiles in clinical isolates of S.
aureus, collected from the three London based hospitals
(LBH) and the main general hospital in Malta. The latest
European Antimicrobial Resistance Surveillance System
(EARSS) annual report [5] showed the proportion of
MRSA bacteraemia across Europe between 2000 to 2008.
The report demonstrated the that Malta has one of the
highest proportion of MRSA bacteraemia in Europe,
between this time the levels of MRSA ranged from 35 to
55%, with the highest level recorded in 2006 at 66%. The
UK had the fifth highest level of MRSA in Europe over
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the same time period ranging from 31-34%, with the
highest level recorded in 2001 at 44% [5]. Both these
countries have reported sustained levels of MRSA bacter-
aemia at approximately 40% since 2001 and therefore rep-
resent counties where MRSA is considered an important
problem.
Materials and Methods
Bacterial strains
Clinical isolates of MRSA and MSSA were collected from
three LBH; Kingston Hospital, Surrey (a general hospital),
The Royal Brompton Hospital (a specialist respiratory
hospital), London; and The Royal Marsden Hospital,
London (a specialist cancer hospital) and from St. Luke's
Hospital, Malta (main general hospital in Malta serving a
population of approximately 400,000 people). Participat-
ing hospitals were selected based upon having different
specialties and so serving specific patient groups or alter-
natively a general hospital with a broad cohort of
patients. A total of 378 isolates were collected from the
LBH (260 MRSA and 118 MSSA) and 309 isolates were
collected from the Maltese hospital (216 MRSA and 93
MSSA). All LBH S. aureus isolates were collected over an
18 month period (07/2002-12/2004) and the Maltese iso-
lates were collected over an 8 month period (02/2003-10/
2003). All bacterial isolates originated from swab samples
taken from patients admitted to the study hospitals.
Duplicate isolates from patient samples were excluded
from the study. No further individual patient data was
made available.
All isolates were also transferred to 1 ml aliquot of
Brain-heart infusion broth (Oxoid Ltd), containing 15%
glycerol (Sigma Ltd) and frozen at -80°C. The following S.
aureus strains were used as controls during the experi-
ment: MRSA NCTC 12493 (Control 1) and Oxford S.
aureus NCTC06571 (Control 2), a strain sensitive to all
antibiotics in the test panel.
Isolates confirmation
Isolate identification was primarily determine in respec-
tive hospital. Identification of isolates was reconfirmed in
the author's laboratory using a standard method (Gram
staining and coagulase production using staphylase test
(Oxoid, UK).
Antibiogram testing
The antibiotic panel consisted of 14 different antimicro-
bials. Thirteen were tested using standard operating pro-
cedures defined by the BSAC Version 3 2004 [6]. In
addition, vancomycin sensitivity was assayed using a pre-
viously published protocol [7]. The following antibiotics
were tested using BSAC methodology: 30 μg amikacin, 10
μg chloramphenicol, 1 μg ciprofloxacin, 2 μg clarithromy-
cin, 2 μg clindamycin, 5 μg erythromycin, 10 μg gentami-
cin, 10 μg linezolid, 5 μg methicillin, 1 unit penicillin, 2 μg
rifampicin, 30 μg teicoplanin and 10 μg tetracycline
(MAST Diagnostic Ltd).
Vancomycin susceptibility testing
Vancomycin susceptibility was tested using a previously
described method [7].When growth was observed on the
vancomycin plates, the minimum inhibitory concentra-
tion (MIC) of the isolate was determined by E-test (Cam-
bridge Diagnostic Service Ltd). Vancomycin MIC levels
of below 4 mg/L were considered are sensitive and above
4 mg/L was considered as resistant.
Statistical analysis
Statistical analysis was performed using Z-Test, with the
following equation:
KEY: X1- Number of positive LBH isolates, X2- Number
of positive Maltese isolates, N1-Total number of LBH iso-
lates, N2-Total number of Maltese isolates, P1- Population
LBH (X1/N1), P2- Population Malta (X2/N2).
Results and Discussion
The aim of this study was to determine the MAR profiles
for isolates collected from two European study groups,
against a panel of fourteen antibiotics and place this
information within the context of current prescribing
p o l i c i e s  f o r  b o t h  c o h o r t s .  O f  t h e  f o u r t e e n  a n t i b i o t i c s
tested, all isolates were completely sensitive to only three
antibiotics: linezolid, teicoplanin and vancomycin. This
was not surprising since resistance to these antibiotics is
currently rare, due to restricted use of this antibiotic.
However, resistant strains of MRSA to these antibiotics
have been identified in other studies both in the UK and
worldwide [8-16].
When comparing the results between MSSA (Figure 1)
and MRSA isolates (Figure 2), it could be seen that the
MRSA isolates were predominantly resistant to a greater
range of antibiotics. Figure 1 shows the resistance level
for individual antibiotic results for the MSSA isolates
from both isolate groups (LBH and Malta). Of the four-
teen antibiotics used the isolates were resistant to ten of
the antibiotics and all were sensitive to methicillin; in
addition to linezolid, teicoplannin and vancomycin (data
not shown in graph). The highest level of resistance was
recorded with the antibiotic penicillin G in both isolate
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cohorts and high levels of resistance (above 70%) were
also seen to clarithromycin and ciprofloxacin Low levels
of resistance (< 20%) were seen to the antibiotics; amika-
cin, chloramphenicol, rifampicin and tetracycline in both
cohorts, although the level of resistance to tetracycline
was slightly higher in the Maltese group (22%).
Statistical analysis showed a significant difference
between sensitivity of the MSSA to five of the antibiotics
from the LBH and Maltese cohorts (p < 0.05). The LBH
i s o l a t e s  s h o w e d  a  h i g h e r  p e r c e n t a g e  o f  r e s i s t a n c e  t o
clarithromycin and gentamicin, whereas the Maltese iso-
lates showed a higher percentage of resistance to cipro-
floxacin, erythromycin and tetracycline resistance.
Table 1 illustrates the number of MSSA isolates show-
ing resistance a given number of antibiotics of different
groups. The isolates show a range of values with some
strains showing complete sensitivity to the drugs in the
test panel whilst other show resistance to up to eight dif-
ferent antibiotics, with a mean number of resistances of 4
and 3 antibiotics in the LBH and Maltese cohorts respec-
tively.
Figure 2 shows the results for the MRSA isolates from
both countries, these results demonstrate very different
patterns and levels of resistance to the antimicrobials
tested (figure 2) when compared to the MSSA isolates.
With reference to figure 2 it can be seen that resistance
levels of up to 50% were reported to six of the antibiotics
tested in both cohorts. Concentrating on the MRSA iso-
lates from the LBH, it can be seen that resistance levels of
greater than 80% were seen to six of the fourteen antibiot-
ics, namely ciprofloxacin, clarithromycin, clindamycin,
erythromycin, two of which were β-lactams. The total
resistance to the β-lactam antibiotics is unsurprising as
all isolates in figure 2 are MRSA and therefore inherently
resistant to this class of antibiotic. The high levels of
resistance seen to erythromycin, clarithromycin and clin-
damycin, may in part be due to a single resistance mecha-
nism that affect all of these antibiotics. These three
antibiotics share a similar mode of action against the bac-
terial cell effecting the 50s ribosomal subunit and belong
to the; Macrolides (erythromycin, clarithromycin), Lin-
cosamides (clindamycin) and Streptogramins (MLS) class
of antibiotic. There are two common mechanisms of
resistance against MLS antibiotics, the first encoding by
the erm gene, leads to the modification of the target ribo-
some, whereas the second mechanisms of resistance is
mediated by two classes of active efflux pumps [17].
Figure 1 A Graph illustrating the percentage of methicillin-sensitive S. aureus isolates showing resistance to a panel of antibiotics (no re-
sistance was detected for the antibiotics: methicillin, vancomycin, linezolid and tecioplanin). MSSA Isolates were collected from LBH (n = 114) 
and Malta (n = 93). KEY: Black bar represents LBH MSSA isolates and white bars represent Maltese MSSA isolates.
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The Z-test showed significant differences in the level of
resistance to both clarithromycin and gentamicin in the
LBH isolates (p < 0.05) when compared to the Maltese
MRSA isolates. Interestingly, the Maltese isolates showed
increased levels of resistance to tetracycline when com-
pared to the LBH strains (p < 0.05).
The MRSA isolates from both countries were resistant
to between 2 and 10 antibiotics, with a mean resistance to
six of the antimicrobials in the panel (LBH and Maltese
isolates respectively; Table 1).
Previous work carried out by the current authors inves-
tigated the strain types within the culture collection by
pulse field gel electrophoresis (PFGE). The results of this
work showed that the isolates from the two countries had
similar DNA profile patterns. The majority of the isolates
collected from the UK and Malta were determined to be
epidemic MRSA (EMRSA) -15 (53% and 59%; UK and
Malta respectively) and -16 (14.3% and 2.1% UK and
Malta respectively). A distinct strain was found in the
Maltese group which the authors determined to be a local
EMRSA particular to Malta and accounted for (14.4%).
No correlation of MAR profiles and strain type could be
determined [18].
It is proposed that the data presented could contribute
to the improvement of current antibiotic prescription
policies (APP). In the APP from the LBH, gentamicin is
Figure 2 Graph illustrating the percentage of methicillin-resistant S. aureus isolates showing resistance to a panel of antibiotics (no resis-
tance was detected for the antibiotics: vancomycin, linezolid and tecioplanin). MRSA isolates were collected from LBH (n = 257) and Malta (n = 
216). KEY: Black bar represents LBH MRSA isolates and white bars represent Maltese MRSA isolates.
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Table 1: The percentage of isolates within a specified cohort showing resistance to a given number of antibiotics (N = 0-10 
antibiotics)
Isolates The number of antimicrobials to which isolates were resistant.
0 1 23456789 1 0
LBH MSSA 0.8 5.1 16.1 28 24.6 19.5 2.5 1.7 1.7 ---- ----
LBH MRSA ---- ---- 1.2 1.5 5.4 6.5 36.5 28.1 14.7 4.6 1.5
Maltese MSSA 3.2 7.5 18.3 25.8 22.6 12.9 6.5 2.2 1 ---- ----
Maltese MRSA ---- ---- 0.5 5.6 10.6 9.3 29.6 28.2 10.2 4.6 1.4Gould et al. Annals of Clinical Microbiology and Antimicrobials 2010, 9:20
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advocated to treat MSSA infection [19]; however, using
the data recorded in this study the use of this antibiotic
would be limited, due to high levels of resistance (60%).
These resistance levels would suggest that in three out of
five cases treatment with gentamicin would potentially
fail. In Malta the AAP for MSSA infection are clarithro-
mycin and clindamycin [20]; once again using the data
recorded in this study the use of clindamycin would be
limited as resistance to this antibiotic was demonstrated
to be 55%. Furthermore 29% of the MSSA isolates would
also be resistance to clarithromycin, interestingly of these
isolate 82% (22/27) were resistance to both clarithromy-
cin and clindamycin. This would mean that for almost
one quarter of isolates the current treatment would fail.
Both in the UK and Malta this could lead to an increase in
hospitalisation and progression of infection following
treatment failure. These observations highlight the need
for a clear understanding of the dynamics of local antibio-
gram profiles which can then inform local prescribing
policy. For isolates that are methicillin-resistant, vanco-
mycin is advocated [19], a similar situation is observed in
Maltese hospitals [20]. With the data from this current
study, vancomycin as a form of treatment would work in
all cases of MRSA investigated in this study. A recent sur-
vey examined the antibiotics used in the treatment of
MRSA infection in the UK, the findings of this work
showed that main treatment consisted of vancomycin
singly or in combination [21]. Whilst resistance to this
antibiotic remains rare cases have been reported [8,9,11]
and therefore increased application may potentially drive
the future development of vancomycin resistant strains.
MAR profiles as well as resistance levels to individual
antibiotics were determined from the data in this study.
This data yielded a large number of different MAR pro-
files but the frequency of appearance in most cases was
extremely low. As a consequence a frequency cut off
value was implemented with MAR profiles containing 10
or more isolates being included in the analysis. The
MSSA cohort contained 45 (LBH) and 52 (Malta) pro-
files; a total of nine profiles were present in both coun-
tries. The majority of profiles contained less than ten
isolates; however, two profiles (one from each cohort)
contained ten or more isolates. The profile (gentamicin,
penicillin G and clarithromycin) in the LBH cohort con-
tained seventeen isolates (15%, 17/114) and the second
profile from the Maltese group (penicillin G and cipro-
floxacin) contained ten isolates (11%, 10/93).
Within the MRSA groups a total of 42 MAR profiles
were identified in the LBH isolates and 62 profiles in the
Maltese strains with 22 profiles being common to both
countries. The predominant MAR profiles from both
countries can be seen in Table 2, these profiles accounted
for 66% (170/256) of the isolates from the LBH and 48%
(104/216) of the Maltese isolates. The remaining profiles
in both cohorts, containing between one to ten isolates,
accounted for 34% (86/256) of the LBH and 52% (112/
216) of the Maltese isolates. The most frequent profile
within LBH and Maltese MRSA cohorts contained a
combination of six and seven antibiotics, with a MAR
profile both containing penicillin G, methicillin, cipro-
floxacin, clindamycin, clarithromycin and erythromycin
(Table 2). A recent study by Comceoção and colleagues
[22] examined the MAR profiles from a small hospital in
the Azorean islands. This group found two predominant
profiles in circa 86% of MRSA isolates (consisting of pro-
file one; methicillin, penicillin, ciprofloxacin and erythro-
mycin and profile two; methicillin, penicillin and
ciprofloxacin). They also reported that all their isolates
were sensitive to linezolid, teicoplanin and vancomycin
[22], this sensitivity profile was also observed in the iso-
lates in the current study. A second study by Gales and
colleagues (2009) determined antimicrobial resistance
levels in clinical isolates of MRSA in Brazil [23]. This
study reported that these isolates were highly resistant to
Table 2: Illustrates the predominant multiple antibiotic resistant (MAR) profiles identified in the MRSA isolates from the 
LBH and Malta
Multiple antibiotic-resistant (MAR) profiles Percentage (%) of isolates showing the indicated resistance pattern.
LBH (n = 256) Malta (n = 216)
AK, G, PG, M, CD, E, Clar, Cip 5.1 -
Ak, PG, M, C, CD, E, Clar, Cip 4.7 -
Ak, PG, M, CD, E, Clar, Cip 4.3 -
G, PG, M, CD, E, Clar, Cip 12.8 -
PG, M, C, CD, E, Clar, Cip 8.2 20.8
PG, M, CD, E, Clar, Cip 31.1 21.8
PG, M, Cip - 5.6
AK: amikacin; C: chloramphenicol; Cip: ciprofloxacin; Clar: clarithromycin; CD: clindamycin; E: erythromycin; G: genatmicin; M: methicillin and 
PG: penicillin G.Gould et al. Annals of Clinical Microbiology and Antimicrobials 2010, 9:20
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erythromycin (94%), clindamycin (87.9%) and ciprofloxa-
cin (91.4%). Another study focusing on MRSA isolates
collected from a cutaneous infection in a pediatric
department demonstrated resistance levels of 70.5% to
erythromycin in isolates of MRSA [24]. Despite these
studies (including the current work) being carried out in
different countries and in varying clinical settings, high
levels of resistance to erythromycin, clindamycin and cip-
rofloxacin were evident in all cases. These particular anti-
biotics are well used and commonly indicated in
treatment policies so increased levels of resistance is not
surprising. It is clear that monitoring resistance levels and
updating prescribing policies is not only good clinical
practice, but also more cost-effective for the hospitals in
terms of minimising long hospital stays and the use of
antibiotics to which the bacterium may be resistant.
Inappropriate use of antibiotics is well known, studies
carried out in the 1990's suggested that as many as 50% of
prescription policies were not fully effective [25,26].
Indeed data from the current study suggests that there
might be potential for treatment failure against MSSA
infection due to an increase in resistance in both the UK
and Maltese isolates.
This may, then lead on to challenges in terms of resis-
tance and selective pressure, Burke (1998) [27] recogn-
ised that resistance to antibiotic was easy to promote but
difficult to reverse. This can clearly be seen in the rise of
MRSA infection in the UK, in 1991 MRSA only
accounted for 2% of bacteraemia cases caused by S.
aureus, however by 2000, MRSA represented 42% of S.
aureus isolates from bacteraemia cases [2]. It is encourag-
ing to note that this level of resistance has decreased from
2000, to 32% in 2008 [5]. Therefore the question remains:
do we need to revaluate the way the proscription policies
are determined locally and nationally?
Cooke and Holmes [28] proposed there need to be bet-
ter antibiotic stewardship, in the possible form of "antibi-
otic care bundle" (ACB) [28]. These care bundles aim to
select antibiotics that are most likely to present a fully
therapeutic solution, whilst reducing both potential side
effects and the risk of developing resistance to the antibi-
otic in use. Some of the key components suggested by the
authors indicate that the bundle should be adapted for
local needs and the policy should have input from local
microbiologists and pharmacists. However the authors
did not define what they determined to be local. It may be
speculated that within one hospital, different wards or
clinical areas may require their only ACB. The authors
also suggest that the prescribing policy should be moni-
tored and altered when and if required, following the
apparent development of resistance to one or more anti-
biotics [28].
Antibiotic care bundles has been implemented in Scot-
land since 2005 and are run by a multidisciplinary antimi-
crobial management team (AMT) consists of; lead
doctor, pharmacist, microbiologist and a representative
of senior management [29]. Two recent reports from the
USA have demonstrated the potential of ACB in reducing
antibiotic resistance in addition to show the cost effec-
tiveness and potential saving on drug treatment [30,31].
Drew (2009) [30] although does highlight the possible dif-
ficulty in implementing ACB such as; the need of appro-
priate personnel to run the project, initial funding of the
project both financially and the time that needs to be
assigned to the project, as well as potentially resistant to
the ACB from colleagues. However on balance the find-
ing of these studies show the potential benefit of ACB out
weight the initial problem, but understanding the local
microbial antibiotic resistance pattern within a hospital
would be required before any care bundle could be devel-
oped and implemented.
Conclusion
In conclusion, this report shows that two study groups
geographically separated by large distances have similar
antibiotic resistance profiles in their hospital isolates of S.
aureus, despite differences in antibiotic treatment regi-
mens indicated in the respective hospital policies. The
importance of monitoring the level of not only methicillin
resistance but also the resistance levels of other antibiot-
ics is also clearly demonstrated. Currently in the UK, the
government has introduced a mandatory reporting
scheme for methicillin resistance in S. aureus. Due to the
high level of resistance recorded to some of the antibiot-
ics used in this study, it could be suggested that this type
of scheme needs to be extended to include other antibiot-
ics where there is the potential for resistance level to
reach 100%. The data presented in this paper suggests
that the continued monitoring of local antibiotic resis-
tance profiles is essential. The resultant epidemiology is
important in informing local prescribing policies and the
early identification of emerging resistance patterns,
allowing for the production of responsive therapy regi-
mens in response to ever changing microbial challenges.
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